Interactive Clinical Scenarios: Navigating the Expanding Treatment Landscape for Relapsed and/or Refractory Multiple Myeloma - priME Oncology

Interactive Clinical Scenarios: Navigating the Expanding Treatment Landscape for Relapsed and/or Refractory Multiple Myeloma

Not a member of My prIME? Join now for instant access.

Interactive Clinical Scenarios: Navigating the Expanding Treatment Landscape for Relapsed and/or Refractory Multiple Myeloma

View Activity
View Activity

Activity Overview

This activity consists of expert discussions by Dr Sagar Lonial on clinical cases of two different patients with relapsed and/or refractory multiple myeloma (MM). These discussions consider diagnosis, staging, and selecting from the numerous treatment options available to patients with MM.

Provider

This activity is provided by prIME Oncology.

Support

This educational activity is supported by Onyx Pharmaceuticals, an Amgen Subsidiary and Takeda Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you.

Technical requirements may be found under the Terms of Use.

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 75% or higher.

Disclosure of Relevant Financial Relationships

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Lonial has disclosed that he has received consulting fees from Bristol-Myers Squibb, Celgene Corporation, Millennium, Novartis Oncology, and Sanofi. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
The employees of prIME Oncology have disclosed:

  • Janice Galleshaw, MD (medical content reviewer) – no relevant financial relationships
  • Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.